Implementation of European Society of Gastrointestinal Endoscopy (ESGE) recommendations for small-bowel capsule endoscopy into clinical practice: Results of an official ESGE survey.


Journal

Endoscopy
ISSN: 1438-8812
Titre abrégé: Endoscopy
Pays: Germany
ID NLM: 0215166

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 29 7 2021
medline: 14 9 2021
entrez: 28 7 2021
Statut: ppublish

Résumé

We aimed to document international practices in small-bowel capsule endoscopy (SBCE), measuring adherence to European Society of Gastrointestinal Endoscopy (ESGE) technical and clinical recommendations. Participants reached through the ESGE contact list completed a 52-item web-based survey. 217 responded from 47 countries (176 and 41, respectively, from countries with or without a national society affiliated to ESGE). Of respondents, 45 % had undergone formal SBCE training. Among SBCE procedures, 91 % were performed with an ESGE recommended indication, obscure gastrointestinal bleeding (OGIB), iron-deficiency anemia (IDA), and suspected/established Crohn's disease being the commonest and with higher rates of positive findings (49.4 %, 38.2 % and 53.5 %, respectively). A watchful waiting strategy after a negative SBCE for OGIB or IDA was preferred by 46.7 % and 70.3 %, respectively. SBCE was a second-line exam for evaluation of extent of new Crohn's disease for 62.2 % of respondents. Endoscopists adhered to varying extents to ESGE technical recommendations regarding bowel preparation ( > 60 %), use in those with pacemaker holders (62.5 %), patency capsule use (51.2 %), and use of a validated scale for bowel preparation assessment (13.3 %). Of the respondents, 67 % read and interpreted the exams themselves and 84 % classified exams findings as relevant or irrelevant. Two thirds anticipated future increase in SBCE demand. Inability to obtain tissue (78.3 %) and high cost (68.1 %) were regarded as the main limitations, and implementation of artificial intelligence as the top development priority (56.2 %). To some extent, endoscopists follow ESGE guidelines on using SBCE in clinical practice. However, variations in practice have been identified, whose implications require further evaluation.

Sections du résumé

BACKGROUND
We aimed to document international practices in small-bowel capsule endoscopy (SBCE), measuring adherence to European Society of Gastrointestinal Endoscopy (ESGE) technical and clinical recommendations.
METHODS
Participants reached through the ESGE contact list completed a 52-item web-based survey.
RESULTS
217 responded from 47 countries (176 and 41, respectively, from countries with or without a national society affiliated to ESGE). Of respondents, 45 % had undergone formal SBCE training. Among SBCE procedures, 91 % were performed with an ESGE recommended indication, obscure gastrointestinal bleeding (OGIB), iron-deficiency anemia (IDA), and suspected/established Crohn's disease being the commonest and with higher rates of positive findings (49.4 %, 38.2 % and 53.5 %, respectively). A watchful waiting strategy after a negative SBCE for OGIB or IDA was preferred by 46.7 % and 70.3 %, respectively. SBCE was a second-line exam for evaluation of extent of new Crohn's disease for 62.2 % of respondents. Endoscopists adhered to varying extents to ESGE technical recommendations regarding bowel preparation ( > 60 %), use in those with pacemaker holders (62.5 %), patency capsule use (51.2 %), and use of a validated scale for bowel preparation assessment (13.3 %). Of the respondents, 67 % read and interpreted the exams themselves and 84 % classified exams findings as relevant or irrelevant. Two thirds anticipated future increase in SBCE demand. Inability to obtain tissue (78.3 %) and high cost (68.1 %) were regarded as the main limitations, and implementation of artificial intelligence as the top development priority (56.2 %).
CONCLUSIONS
To some extent, endoscopists follow ESGE guidelines on using SBCE in clinical practice. However, variations in practice have been identified, whose implications require further evaluation.

Identifiants

pubmed: 34320664
doi: 10.1055/a-1541-2938
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

970-980

Informations de copyright

European Society of Gastrointestinal Endoscopy. All rights reserved.

Déclaration de conflit d'intérêts

X. Dray is a co-founder of and shareholder in Augmented Endoscopy (from July 2019, ongoing); he has provided consultancy to Norgine (January to December 2020); he holds a patent for a device and method for classifying the quality of digestive capsule endoscopy image. R. Eliakim has provided consultancy to Medtronic (from 2016, ongoing). M. Keuchel has provided consultancy to and received speaker’s fees from Medtronic; he has received a speaker’s fee from Olympus; he is the co-editor of a book on capsule endoscopy. A. Koulaouzidis is a consultant for Jinshan (from March 2021, ongoing); he is a co-director of iCERV (from June 2020, ongoing); he is a co-founder of and a stakeholder in AJM Medicaps (from March 2021, ongoing). S. Panter has provided consultancy for and has received support for research projects from Medtronic. E. Rondonotti has received speaker honoraria from Fujifilm. B. Rosa has provided consultancy for and has received sponsorship from Medtronic (from 2020, ongoing). C. Spada has provided consultancy to Medtronic (from 2017 to 2021). E. Toth has provided consultancy to and received a lecture fee from Medtronic (2017 to 2021) and Norgine 2018 to 2021). H. Beaumont, P. Bhandari, P. Ellul, I. Fernandez-Urien, R. Jover, L.-D. Lazaridis, K. Triantafyllou, and G. Tziatzios, declare no competing interests.

Auteurs

Lazaros-Dimitrios Lazaridis (LD)

Hepatogastroenterology Unit, Second Department of Internal Medicine - Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.

Georgios Tziatzios (G)

Hepatogastroenterology Unit, Second Department of Internal Medicine - Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.

Ervin Toth (E)

Department of Gastroenterology, Skåne University Hospital, Malmö, Lund University, Sweden.

Hanneke Beaumont (H)

Department of Gastroenterology, Amsterdam University Medical Center, location VUMC, Amsterdam, The Netherlands.

Xavier Dray (X)

Sorbonne University, Center for Digestive Endoscopy, Hôpital Saint Antoine, APHP, Paris, France.

Rami Eliakim (R)

Sheba Medical Center, Department of Gastroenterology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Pierre Ellul (P)

Division of Gastroenterology, Mater Dei Hospital, Malta.

Ignacio Fernandez-Urien (I)

Complejo Hospitalario de Navarra, Pamplona, Spain.

Martin Keuchel (M)

Clinic for Internal Medicine, Agaplesion Bethesda Krankenhaus Bergedorf, Hamburg, Germany.

Simon Panter (S)

Department of Gastroenterology, South Tyneside District Hospital, South Tyneside and Sunderland NHS Foundation Trust, South Shields, UK.

Emanuele Rondonotti (E)

Gastroenterology Unit, Valduce Hospital, Como, Italy.

Bruno Rosa (B)

Gastroenterology Department, Hospital da Senhora da Oliveira, Guimarães, Portugal.

Cristiano Spada (C)

Digestive Endoscopy Unit and Gastroenterology, Fondazione Poliambulanza, Brescia, Italy.

Rodrigo Jover (R)

Servicio de Medicina Digestiva. Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria ISABIAL, Alicante, Spain.

Pradeep Bhandari (P)

Department of Gastroenterology, Queen Alexandra Hospital Portsmouth, Portsmouth, UK.

Konstantinos Triantafyllou (K)

Hepatogastroenterology Unit, Second Department of Internal Medicine - Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.

Anastasios Koulaouzidis (A)

Pomeranian Medical University, Department of Social Medicine and Public Health, Faculty of Health Science, Szczecin, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH